Farxiga® (dapagliflozin)
for Diabetes Type 2

Farxiga (dapagliflozin) is an oral SGLT2 inhibitor that improves blood sugar control in type 2 diabetes, reduces heart failure-related risks, and slows kidney disease progression. It works by preventing glucose reabsorption in the kidneys, increasing its excretion, and reducing sodium reabsorption to support heart and kidney function.

Heart
Medication Guide Icon Medication Guide
TV Commercial Icon TV Commercial
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Diabetes Type 2